JP2016510317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510317A5 JP2016510317A5 JP2015549826A JP2015549826A JP2016510317A5 JP 2016510317 A5 JP2016510317 A5 JP 2016510317A5 JP 2015549826 A JP2015549826 A JP 2015549826A JP 2015549826 A JP2015549826 A JP 2015549826A JP 2016510317 A5 JP2016510317 A5 JP 2016510317A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- ameliorating
- treating
- preventing
- neurodegenerative disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 40
- 230000004770 neurodegeneration Effects 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 38
- 208000015122 neurodegenerative disease Diseases 0.000 claims 38
- 229910052805 deuterium Inorganic materials 0.000 claims 26
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 239000001301 oxygen Chemical group 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 229920006395 saturated elastomer Polymers 0.000 claims 10
- 229910052717 sulfur Chemical group 0.000 claims 10
- 239000011593 sulfur Chemical group 0.000 claims 10
- 239000002253 acid Substances 0.000 claims 7
- 150000002148 esters Chemical class 0.000 claims 7
- 230000001154 acute effect Effects 0.000 claims 6
- 201000006417 multiple sclerosis Diseases 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 125000001931 aliphatic group Chemical group 0.000 claims 5
- 229960004419 dimethyl fumarate Drugs 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 4
- 208000023105 Huntington disease Diseases 0.000 claims 4
- 206010028570 Myelopathy Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 4
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 4
- 208000009174 transverse myelitis Diseases 0.000 claims 4
- -1 2- (benzoyloxy) ethyl methyl Chemical group 0.000 claims 3
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims 3
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims 3
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010012305 Demyelination Diseases 0.000 claims 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims 2
- 206010048999 Leukoencephalomyelitis Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 206010037764 Radiation myelopathy Diseases 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 206010061811 demyelinating polyneuropathy Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002008 hemorrhagic effect Effects 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 208000036546 leukodystrophy Diseases 0.000 claims 2
- 210000003007 myelin sheath Anatomy 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 239000002356 single layer Substances 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- XLYMOEINVGRTEX-ONEGZZNKSA-N (e)-4-ethoxy-4-oxobut-2-enoic acid Chemical compound CCOC(=O)\C=C\C(O)=O XLYMOEINVGRTEX-ONEGZZNKSA-N 0.000 claims 1
- URJPHBCJYCQTKQ-NSCUHMNNSA-N 1-o-methyl 4-o-(2-morpholin-4-yl-2-oxoethyl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCC(=O)N1CCOCC1 URJPHBCJYCQTKQ-NSCUHMNNSA-N 0.000 claims 1
- VHYQFUXOHDWOPQ-SNAWJCMRSA-N 1-o-methyl 4-o-(4-morpholin-4-ylbutyl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCCCCN1CCOCC1 VHYQFUXOHDWOPQ-SNAWJCMRSA-N 0.000 claims 1
- 206010017711 Gangrene Diseases 0.000 claims 1
- 150000001975 deuterium Chemical group 0.000 claims 1
- XLYMOEINVGRTEX-UHFFFAOYSA-N fumaric acid monoethyl ester Natural products CCOC(=O)C=CC(O)=O XLYMOEINVGRTEX-UHFFFAOYSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745115P | 2012-12-21 | 2012-12-21 | |
| US61/745,115 | 2012-12-21 | ||
| PCT/US2013/077248 WO2014100728A1 (en) | 2012-12-21 | 2013-12-20 | Deuterium substituted fumarate derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019005219A Division JP2019077711A (ja) | 2012-12-21 | 2019-01-16 | 重水素置換されたフマル酸誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510317A JP2016510317A (ja) | 2016-04-07 |
| JP2016510317A5 true JP2016510317A5 (enExample) | 2017-02-09 |
| JP6506174B2 JP6506174B2 (ja) | 2019-04-24 |
Family
ID=49943593
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549826A Expired - Fee Related JP6506174B2 (ja) | 2012-12-21 | 2013-12-20 | 重水素置換されたフマル酸誘導体 |
| JP2019005219A Pending JP2019077711A (ja) | 2012-12-21 | 2019-01-16 | 重水素置換されたフマル酸誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019005219A Pending JP2019077711A (ja) | 2012-12-21 | 2019-01-16 | 重水素置換されたフマル酸誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20140179779A1 (enExample) |
| EP (2) | EP3566701A1 (enExample) |
| JP (2) | JP6506174B2 (enExample) |
| CN (1) | CN105142628A (enExample) |
| AR (1) | AR094277A1 (enExample) |
| ES (1) | ES2733961T3 (enExample) |
| TW (1) | TW201436790A (enExample) |
| WO (1) | WO2014100728A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2334378B1 (en) | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| NZ618178A (en) | 2011-06-08 | 2016-03-31 | Biogen Ma Inc | Process for preparing high purity and crystalline dimethyl fumarate |
| JP2015527372A (ja) | 2012-08-22 | 2015-09-17 | ゼノポート，インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
| US9597292B2 (en) | 2012-08-22 | 2017-03-21 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| JP6506174B2 (ja) * | 2012-12-21 | 2019-04-24 | バイオジェン エムエー インコーポレイテッド | 重水素置換されたフマル酸誘導体 |
| CA2992211C (en) | 2013-03-14 | 2021-09-21 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| CN104415026A (zh) * | 2013-08-31 | 2015-03-18 | 成都渊源生物科技有限公司 | 氘代富马酸衍生物在治疗多发性硬化症中的应用 |
| TW201516020A (zh) | 2013-09-06 | 2015-05-01 | Xenoport Inc | （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途 |
| AU2015218587B2 (en) | 2014-02-24 | 2017-04-27 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| AU2015222880B2 (en) | 2014-02-28 | 2016-11-24 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| MA40990A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle |
| AU2016231883B2 (en) * | 2015-03-17 | 2019-03-07 | Hetero Labs Limited | Pharmaceutical compositions of dimethyl fumarate |
| MA41785A (fr) | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
| WO2017060420A1 (en) | 2015-10-07 | 2017-04-13 | Neurovive Pharmaceutical Ab | Protected fumaric acid-based metabolites for the treatment of autoimmune diseases |
| HUE052269T2 (hu) | 2016-02-03 | 2021-04-28 | Rigel Pharmaceuticals Inc | NRF2-t aktiváló vegyületek és alkalmazásuk |
| MX2019005401A (es) * | 2016-11-08 | 2019-08-05 | Reata Pharmaceuticals Inc | Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma. |
| CN106946701B (zh) | 2017-03-28 | 2020-05-15 | 重庆纽源生物科技有限公司 | 一种水杨酸基富马酸盐衍生物及在治疗帕金森症和其他神经退行性疾病应用 |
| WO2020094767A1 (en) | 2018-11-08 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of nrf2 activators for the treatment of staphylococcus aureus infections |
| CN109364058A (zh) * | 2018-12-05 | 2019-02-22 | 中南大学湘雅医院 | 富马酸酯及其可药用盐在制备治疗铁死亡相关疾病的药物中的应用 |
| WO2020214693A1 (en) * | 2019-04-17 | 2020-10-22 | Ixchel Pharma, Llc | Prodrugs of monomethyl fumarate |
| US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| CA3182369A1 (en) | 2020-05-06 | 2021-07-22 | Imcyse Sa | Combination treatment for fumarate-related diseases |
| CN112675159A (zh) * | 2021-01-12 | 2021-04-20 | 杭州师范大学 | L-苹果酸在制备防治肝脏缺血再灌注损伤药物中的应用 |
| US20260053777A1 (en) | 2022-09-02 | 2026-02-26 | Institut National de la Santé et de la Recherche Médicale | Use of nrf2 activators for the treatment of cerebral small vessel disease |
| CN116440113A (zh) * | 2023-03-27 | 2023-07-18 | 天津农学院 | 富马酸二甲酯作为t-2毒素神经保护剂方面的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3819738A1 (de) * | 1988-06-10 | 1989-12-14 | Stockhausen Chem Fab Gmbh | Drei funktionelle estergruppen enthaltende verbindungen, zwischenprodukte zu ihrer herstellung, ihre herstellung und verwendung |
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| DE19814358C2 (de) | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
| DE19839566C2 (de) | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| DE19848260C2 (de) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DE10000577A1 (de) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| DE10101307A1 (de) | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| AU2002219236B2 (en) | 2001-01-12 | 2006-02-09 | Biogen International Gmbh | Fumaric acid amides |
| DE10217314A1 (de) | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
| CA2526586C (en) | 2003-09-09 | 2010-03-16 | Biogen International Gmbh | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| EP1799196B1 (en) | 2004-10-08 | 2016-06-22 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| EP1812374A1 (en) | 2004-11-10 | 2007-08-01 | Aditech Pharma AB | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| DE102005022845A1 (de) | 2005-05-18 | 2006-11-23 | Fumapharm Ag | Thiobernsteinsäurederivate und deren Verwendung |
| WO2007006307A2 (en) | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| WO2007006308A1 (en) | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use |
| WO2007042034A1 (en) | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| EP1940382A2 (en) | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| EP2139467B1 (en) | 2007-02-08 | 2016-09-21 | Biogen MA Inc. | Neuroprotection in demyelinating diseases |
| EP2680006A1 (en) | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Treatment for Amyotrophic Lateral Sclerosis |
| US20110160253A1 (en) | 2008-05-28 | 2011-06-30 | Harbeson Scott L | Deuterated tizanidine |
| EP2334378B1 (en) * | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| WO2010126605A1 (en) * | 2009-04-29 | 2010-11-04 | Biogen Idec Ma Inc. | Treatment of neurodegeneration and neuroinflammation |
| MX337605B (es) * | 2010-01-08 | 2016-03-10 | Catabasis Pharmaceuticals Inc | Derivados de fumarato de acido graso y sus usos. |
| HUE025878T2 (en) | 2010-02-12 | 2016-05-30 | Biogen Ma Inc | Neuroprotection in demyelinating diseases |
| KR20140036257A (ko) | 2011-05-26 | 2014-03-25 | 바이오겐 아이덱 엠에이 인코포레이티드 | 다발성 경화증 치료 및 미엘린 함량 보존 및/또는 증가 방법 |
| NZ618178A (en) | 2011-06-08 | 2016-03-31 | Biogen Ma Inc | Process for preparing high purity and crystalline dimethyl fumarate |
| EP2791181A4 (en) | 2011-12-16 | 2015-08-05 | Biogen Ma Inc | SILICONE-CONTAINING FUMIC ACID ESTERS |
| CN114146079A (zh) | 2012-02-07 | 2022-03-08 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
| TWI486339B (zh) * | 2012-02-07 | 2015-06-01 | Xenoport Inc | □啉烷基反丁烯二酸化合物、醫藥組成物以及使用之方法 |
| JP6506174B2 (ja) * | 2012-12-21 | 2019-04-24 | バイオジェン エムエー インコーポレイテッド | 重水素置換されたフマル酸誘導体 |
| US9868690B2 (en) * | 2012-12-21 | 2018-01-16 | Ratiopharm Gmbh | Prodrugs of monomethyl fumarate (MMF) |
| CN104415026A (zh) | 2013-08-31 | 2015-03-18 | 成都渊源生物科技有限公司 | 氘代富马酸衍生物在治疗多发性硬化症中的应用 |
-
2013
- 2013-12-20 JP JP2015549826A patent/JP6506174B2/ja not_active Expired - Fee Related
- 2013-12-20 ES ES13818958T patent/ES2733961T3/es active Active
- 2013-12-20 EP EP19167143.7A patent/EP3566701A1/en not_active Withdrawn
- 2013-12-20 AR ARP130105025A patent/AR094277A1/es unknown
- 2013-12-20 US US14/136,990 patent/US20140179779A1/en not_active Abandoned
- 2013-12-20 WO PCT/US2013/077248 patent/WO2014100728A1/en not_active Ceased
- 2013-12-20 EP EP13818958.4A patent/EP2934503B1/en not_active Not-in-force
- 2013-12-20 CN CN201380073599.5A patent/CN105142628A/zh active Pending
- 2013-12-20 TW TW102147528A patent/TW201436790A/zh unknown
-
2014
- 2014-03-07 US US14/201,380 patent/US10399924B2/en active Active
-
2019
- 2019-01-16 JP JP2019005219A patent/JP2019077711A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510317A5 (enExample) | ||
| US20220071929A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| JP2016534063A5 (enExample) | ||
| JP2020514318A5 (enExample) | ||
| JP2017511339A5 (enExample) | ||
| JP2009514874A5 (enExample) | ||
| JP2014513046A5 (enExample) | ||
| JP2011051993A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2015509534A5 (enExample) | ||
| RU2015143610A (ru) | Лечение катаплексии | |
| JP2013523893A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2015535247A5 (enExample) | ||
| JP2020534270A5 (enExample) | ||
| JP2017506257A5 (enExample) | ||
| JP2018537513A5 (enExample) | ||
| JP2014515407A5 (enExample) | ||
| JP2020500868A5 (enExample) | ||
| JP2016537432A5 (enExample) | ||
| JP2017516829A5 (enExample) | ||
| JP2020533402A5 (enExample) | ||
| JP2018530612A5 (enExample) | ||
| RU2017137008A (ru) | Антагонисты толл-подобного рецептора 4 и применение при аутоиммунных заболеваниях печени | |
| DK2625180T3 (en) | Porphyrinbehandling neurodegenerative diseases |